

SUBJECT INDEX TO VOLUME 2

Adrenomedullin	283	pulse wave velocity in	98
biochemistry of	283	structural/functional factors influencing	98
biological actions of	283	Atherosclerosis	237
cardiovascular/renal protective effects of	289	vasoconstrictor human urotensin II	237
human studies of	285	Benign prostatic hyperplasia (BPH)	301
in animal models of hypertension	288	due to hyperinsulinemia	302
in cardiovascular/renal disease associated		in development of clinical prostate cancer	305
with hypertension	287	medical care implications for	307
in essential hypertension	286	metabolic syndrome by	301
in hypertension	283	Blood pressure (BP)	1,48,127
in hypertensive organ damage	283	ambulatory measurement of	135
in insulin resistance	291	effect of emotional stress	135
in pheochromocytoma	287	effect of job stress	127
in secondary hypertension	287	in elderly	1
<i>in vitro</i>	289	in hypertension	135
<i>in vivo</i>	290	studies with pioglitazone	49
long-term modulation of blood pressure by	288	values of	1
production of	286	variability of values of	3
Aldosterone	21,113	Calcium channel blockers	103
adverse cardiovascular effects of	22	classification of	103
as cardiovascular hormone	25	effect on heart	104
biological effects of	22	in atherosclerosis	106
biosynthesis of	21	in chronic kidney diseases	106
blockade in cardiovascular disease	25	in hypertensive treatment	103
cardiovascular aspects of	119	Calcium channels	103
effects of ACTH on secretion of	115	classification of	103
effects on kidney	23	Cardiac hypertrophy	163,264
effects on vasculature	23	aortic constriction-induced	264
extra-adrenal production of	24	experimental studies of	163
in essential hypertension	118	Cardiovascular disease	21,159,207,317
in hypertension	25	ambulatory BP monitoring for	209
in low-renin essential hypertension	118	cortisol in	212
in pathogenesis of hypertension	116	in youth/adults	207
mechanism of action of	113	resurgence of aldosterone in	21
mechanism of myocardial damage by	23	role of growth hormone	159
myocardial fibrosis by	23	role of insulin-like growth factor	159
regulation by potassium	115	transcendental meditation program in	
regulation of	21	prevention/treatment of	207
regulation of secretion of	114	treatment of	210
role of renin-angiotensin system	114	treatment/prevention through stress	
to renin ratio (ARR)	26	reduction	207
Anemia	328	versus CRP	317
mechanisms of RAS-modulated	328	Cardiovascular mortality	97
Angiotensin receptor blockers (ARBs)	187	Chronic kidney disease (CKD)	255
Arterial stiffness	97	by microvascular disease	255
as therapeutic target	97	Chronic renal failure	297
effect of alpha/beta-adrenoceptor antagonists	100	cardiovascular mortality in	297
effect of angiotensin converting enzyme		causes of sympathetic activation in	297
(ACE)-inhibitors	100	sympathetic overactivity in patients with	297
effect of angiotensin II receptor antagonists	100	Cognitive impairment	1
effect of calcium channel blockers	99	effect of antihypertensive treatments on	4
effect of diuretics	100	in elderly	1
effect of nitrates	99		
effect of vasopeptidase inhibitors	100		
effects of antihypertensive drugs on	99		
measures of	97		
models of	97		
prognostic implications of	99		
pulse wave analysis in	98		

long-term BP variability in	3	production of	326
short-term BP variability in	3	role of AT1 receptor	326
Coronary artery disease (CAD)	139	Essential hypertension	159,207,247
and diabetes	141	ambulatory BP monitoring for	209
clinical presentation of	140	blood pressure reduction studies in	209
effect of age	141	cardiac hypertrophy in	159
in patients with ESRD	140	D ₃ dopamine receptor in	247
noninvasive testing for	141	in youth/adults	207
non-traditional risk factors for	140	plasma glucose concentrations in	159
risk factors for	140	transcendental meditation program in	
therapeutic strategy for	143	prevention/treatment of	207
C-reactive protein	317	Experimental hypertension	193
in cardiovascular disease	318	central cardiovascular control in	193
versus cardiovascular disease	317	neurotransmission alterations in	193
Cystic kidney diseases	167	role of rostral ventrolateral medulla	194
hypertension in children with	167		
		Gasotransmitter	123
D ₃ dopamine receptor	248	in pathogenesis of hypertension	123
effect on renal function	248	role in cardiovascular diseases	123
ETB receptor interaction with	251		
in arteries	248	20-HETE	230
in hypertension	249	effect on renal function/blood pressure	231
interaction of	250	in human hypertension	233
interaction with plasma membrane protein	250	in obesity-induced hypertension	232
interaction with renin-angiotensin-		in pregnant rats	232
aldosterone system	251	synthesis by antisense approaches	230
intracellular messengers for	248		
Dementia	4	Home blood pressure	41
effect of antihypertensive treatments on	4	advantages of	43
relationship between BP and	6	clinical indications of	43
Dopamine receptor	247	devices for	41
localization of	247	in diabetes	44
subtypes in kidney/artery	247	in diagnosis/control of hypertension in	
		primary care	41
Eicosanoids	227	in pregnancy	45
effect on renal function/blood pressure	231	in special populations	44
in human hypertension	233	protocol for	43
in obesity-induced hypertension	232	reference values for	43
in pregnant rats	232		
renal CYP-derived	227	Hydrogen sulfide	123
selective/non-selective inhibitors for		in hypoxic pulmonary hypertension	125
synthesis of	229	in ischemic heart disease	125
synthesis by antisense approaches	230	in pathogenesis of hypertension	123
End-stage renal disease (ESRD)	139,255	in shock	125
by microvascular disease	255	interactions of	125
clinical presentation of	140	production of	123
diagnosis of CAD in	141	regulation of vascular structure/function by	124
macrovascular disease of renal circulation in	255	role in cardiovascular diseases	123
microvascular disease of renal circulation in	255		
noninvasive testing for	141	Hypertension	21,41,61,75,83,113,124,151,168,
prevalence/incidence of CAD in	139	179,227,237,275	
therapeutic strategy for	143	adducin in	276
Erythropoiesis	326	angiotensin converting enzyme inhibitors for	153
by RAS activation	326	angiotensin II type 1 receptor blockers for	154
clinical significance of	329	animal models for	181
molecular mechanism of Ang II-induced		arterial wave reflection in	279
		Brenner/Barker hypotheses for	179
		calcium channels in	76
		changes in ion channels of renal vascular	
		smooth muscle in	75

cytochrome P450 metabolites of arachidonic acid in	77	Isolated systolic hypertension (ISHTN)	271
effect of gender	182	clinical consideration in	272
endogenous ouabain in	276	epidemiology of	271
European project on genes in	275	natural history of	272
gap junctions in	76	pathogenesis of	271
H ₂ S in	124	treatment of	271
heart rate variability in	278	Kidney	61
high blood pressure in	179	Left ventricular hypertrophy	187,201
immune dysfunction in	83	angiotensin II receptor blockade in treatment/	
in children with autosomal dominant polycystic kidney disease (ADPKD)	168	prevention of	188
in children with autosomal recessive polycystic kidney disease (ARPKD)	171	insulin resistance in	203
in children with juvenile nephronophthisis (JNP)	174	pathogenesis of	187
in children with multicystic dysplastic kidney (MCDK)	173	renal involvement in	202
in primary aldosteronism	116	risk factors for	187
intrarenal renin-angiotensin system in	152	role of ARBs	187
intratubular localization of renin-angiotensin system components in	151	role of telmisartan	187
left ventricular structure in	277	trial of telmisartan in	191
lifestyle factors for	182	vascular alterations in	201
low nephron endowment in	179	Left ventricular mass	161
mechanisms of reduced nephron formation in	183	effect of plasma glucose concentrations	161
pathogenesis of	113	MCP-1	265
potassium channels in	76	mediated inflammation/vascular remodeling	265
renin inhibitors for	152	Metabolic syndrome	159,301
resurgence of aldosterone in	21	medical care implications for	307
role of aldosterone	113	role of growth hormone	159
role of renin-angiotensin system	114	role of insulin-like growth factor	159
screening for aldosterone-associated	27	Microalbuminuria	11
vasoconstrictor human urotensin II	237	antihypertensive treatment in	16
Hypertensive cardiovascular remodeling	263	cardiovascular prognosis of	16
Hypertensive hearts	265	cardiovascular risk factors for	12
inflammation in	265	cerebrovascular prognosis of	16
inflammatory changes in	265	effect of blood pressure level	12
Hypothalamus	195	effect of salt sensitivity	14
paraventricular nucleus of	195	effect of smoking	14
Immune system	83	impairment in glomerular permeability in	12
effect of ouabain on	83	pathogenesis of	12
Intratubular renin-angiotensin system	151	prevalence of	12
in hypertension	151	prognostic implications of	16
Ion channels	61	renal prognosis of	16
TRP superfamily of	61	target organ damage by	15
Ion channel architecture	69	Myocardial remodeling	263
of calcium dependent chloride channels	72	in hypertensive hearts	263
of connexins	75	in reactive fibrosis/replacement fibrosis	263
of nonselective cation channels	71	Normal pregnancy	311
of potassium channels	72	AP-A in	312
of renal microvessels	69	ATR in	312
of store operated channels	71	EPC in	312
of transient receptor potential channels	71	Ang-(1-7) in	312
of voltage gated Ca ²⁺ channels	69	Obesity	199
of voltage gated Na ⁺ channels	71	associated hypertension in childhood	199

cardiovascular risk in	201	screening for	35
insulin resistance in	203	therapy of	37
Obstructive sleep apnea	202	Primary hypertension	11,199
Ouabain	83	cardiovascular risk in	201
as endogenous steroid	85	in pediatric age	199
cell death induced by	90	insulin resistance in	203
effect on activation-induced cell death (AICD)	89	microalbuminuria in	11
effect on B lymphocytes	90	pathophysiology of	200
effect on T lymphocyte development	86	renal involvement in	202
effect on T lymphocyte proliferation/ activation	87	Prostate cancer	301
modulation of cytokine production by	88	due to hyperinsulinemia	305,306
		medical care implications for	307
		metabolic syndrome by	301
Perivascular inflammation	263	Renal artery disease	259
mechanisms of	266	clinical presentation of	259
PPAR γ agonists	47	diagnosis of	259
animal studies of	53	Renal cytochrome P ₄₅₀	227
effect on blood pressure	47	biochemistry of	227
human studies of	55	derived eicosanoids	227
in glycemic control	47	in hypertension	227
studies on cell growth	54	Renal disease	298
studies on renal function	54	sympathetic nerve activity in	298
studies on sympathetic nervous system activity	56	therapeutic options for	299
studies on vascular tone/endothelial function	55	Renal ischemia	255
Pre-eclampsia	317	anatomical alterations caused by	257
aetiology/pathogenesis of	317	natural history of	259
as marker of increased cardiovascular risk later in life	318	pathophysiology of damage by	257
incidence/risk factors of	317	renal failure by	255
laboratory findings in	319	Renal microcirculation	69
maternal/perinatal outcome of	318	ion channel architecture of	69
versus cardiovascular disease	317	Renal vascular	69
versus CRP	317	microanatomy of	69
Pregnancy-induced hypertension	311	Renin-angiotensin system (RAS)	219,311,325
Ang-(1-7) in	313	Ang IV/AT ₄ receptor axis in	223
AP-A in	313	angiotensin-(1-7) in	221
ATR in	313	angiotensin-converting enzyme 2 (ACE2) in	219
effect of RAS on EPC in	313	clinical significance of	329
EPC in	314	components of	219
RAS in	313	erythropoietic action of	325
Primary aldosteronism	25,118	functional/therapeutic implications of	223
adrenal imaging of	28	in erythropoiesis	325
causes of	26	in normal pregnancy	311
diagnosis of	27,118	in pregnancy-induced hypertension	311
medical treatment for	28	in vascular endothelial dysfunction	311
prevalence of	25	inhibition on erythropoiesis	327
role of adrenal vein sampling (AVS)	28	pathophysiological roles of	325
surgical treatment for	29	Sodium homeostasis	275
treatment of	28	adducin in	276
Primary hyperaldosteronism	33	arterial wave reflection in	279
confirmatory test for	36	cardiovascular phenotypes in	275
diagnosis of	35	endogenous ouabain in	276
diagnosis of clinical subtypes of	36	genes in	275
differentiating subtypes of	37	heart rate variability in	278
in hypertensive disease	33	left ventricular structure in	277
pathogenesis of	35		
prevalence of	34		

Sympathetic nerve	299	Transient receptor potential channels	61
activity to increased cardiovascular mortality	299	role in hypertension	65
Telmisartan	187	role in plasma membrane Ca ²⁺ transport	63
clinical trials in LVH	189	role in polycystic kidney disease	65
pharmacological properties of	189	role in tubular epithelial Ca ²⁺ transport	64
Transcendental meditation technique (TM)	209	Troglitazone	48
acute effects on CV function	213	associated BP amelioration	53
cost effectiveness of	213	effect on blood pressure	48
decreased serum cholesterol levels by	213	studies with rosiglitazone	50
effect on ambulatory BP in youth	210	Urotensin II	237
effect on cardiovascular mortality	213	and UT receptor system	238
effect on vascular function in youth	210	cellular mechanism of atherosclerosis	
effects on tobacco/alcohol usage	213	induced by	243
impact on hypertension	211	in carotid atherosclerosis	242
in angina pectoris	213	in coronary artery disease	242
in carotid atherosclerosis	213	in hypertension	240
in high school students	209	in metabolic syndrome	241
psychological/physiological mechanisms of	211	in vasoconstriction	240
reduced cardiovascular morbidity by	213	White coat hypertension	147
		atherogenesis in	147